Raymond James & Associates Impel Pharmaceuticals Inc Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 08, 2023
BUY
$2.59 - $4.0 $37,555 - $58,000
14,500 New
14,500 $54,000

Others Institutions Holding IMPL

# of Institutions
1
Shares Held
14.4K
Call Options Held
0
Put Options Held
0
View Full List

About IMPEL PHARMACEUTICALS INC

IMPL Quotes by TradingView
  • Ticker IMPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,738,800
  • Market Cap $475K
  • Description
  • Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...
More about IMPL
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email